1. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer
- Author
-
Akiyuki Sakamoto, Tomonobu Koizumi, Nodoka Sekiguchi, Toshirou Fukushima, Toshiharu Tatai, Takashi Kobayashi, and Shigeru Sasaki
- Subjects
Pulmonary and Respiratory Medicine ,Alectinib ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Pyridines ,medicine.drug_class ,medicine.medical_treatment ,Carbazoles ,Antineoplastic Agents ,Pharmacology ,Dysgeusia ,Crizotinib ,Piperidines ,Carcinoma, Non-Small-Cell Lung ,Internal medicine ,medicine ,Humans ,Anaplastic Lymphoma Kinase ,Lung cancer ,Chemotherapy ,Drug Substitution ,business.industry ,Receptor Protein-Tyrosine Kinases ,Middle Aged ,medicine.disease ,Discontinuation ,ALK inhibitor ,Treatment Outcome ,Toxicity ,Pyrazoles ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
We describe a case of dysgeusia that developed gradually over one week after initiation of crizotinib administration for treatment of ALK-positive non-small cell lung cancer, necessitating discontinuation of the agent. The symptom was accompanied by progressive loss in appetite and body weight. Alectinib, a novel alternative ALK inhibitor, was administered and has been successfully continued without any toxicity, including dysgeusia. The present case indicates that dysgeusia is an important toxicity associated with crizotinib, which could adversely affect nutritional condition and quality of life. We describe the clinical course and present a review of crizotinib-induced dysgeusia.
- Published
- 2015
- Full Text
- View/download PDF